Lead Product(s) : Buloxibutid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lancet's EClinicalMedicine Publishes Phase 2 Data On C21 in COVID-19
Details : C21 is a first-in-class, orally available, low molecular weight, angiotensin II type 2 receptor (AT2R) agonist that activates the “protective arm” of the renin-angiotensin system (RAS) leading to resolution and regeneration following tissue damage.
Product Name : C21
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 25, 2021
Lead Product(s) : Buloxibutid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buloxibutid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vicore Starts Dosing of First COVID-19 Patients in The Global Phase 3 Trial ATTRACT-3
Details : ATTRACT-3 is the pivotal trial in which C21, an angiotensin II type 2 receptor (AT2R) agonist, is tested for the treatment of COVID-19. C21 showed significantly reduced the extended need for supplemental oxygen therapy.
Product Name : C21
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2021
Lead Product(s) : Buloxibutid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Anakinra
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study demonstrated that patients treated with anakinra were significantly more improved than those treated with placebo. Early and targeted use of anakinra, in addition to current SOC, reduces risk of death, reduces ICU admission and increases chance...
Product Name : Kineret
Product Type : Protein
Upfront Cash : Inapplicable
March 09, 2021
Lead Product(s) : Anakinra
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Anakinra
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Hellenic Institute for the Study of Sepsis
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In patients with a poor prognosis, early and targeted use of anakinra in addition to existing standard of care reduced death or progression to severe respiratory failure, while increasing the number of patients discharged with no evidence of COVID-19 inf...
Product Name : Kineret
Product Type : Protein
Upfront Cash : Inapplicable
March 05, 2021
Lead Product(s) : Anakinra
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Hellenic Institute for the Study of Sepsis
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buloxibutid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vicore’s C21 Reduces Long-Term Lung Injury After COVID-19 in the ATTRACT Phase 2 Extension Study
Details : The results showed nearly 50% reduction in lung injury in the C21 group compared with the placebo group suggest that C21 could accelerate recovery and it is currently being evaluated in a phase 3 trial in COVID-19 patients.
Product Name : C21
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2021
Lead Product(s) : Buloxibutid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TAK-919
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Recipharm has reserved capacity to support the anticipated demand for the mRNA-1273 vaccine and is already in the process of recruiting additional staff and making certain investments to enable technology transfer and scale-up to commence imminently.
Product Name : mRNA-1273
Product Type : Vaccine
Upfront Cash : Undisclosed
November 24, 2020
Lead Product(s) : TAK-919
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement